Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-determination study of sugammadex for reversal of rocuronium-induced neuromuscular blockade in children under 2 years of age
2025-521946-82-00Phase 2Authorised
- Sponsor
- CHU Caen Normandie
- Start
- May 2026
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Sugammadex in neuromuscular block (NMB), sponsored by CHU Caen Normandie. Primary endpoints: Total dose of sugammadex required for complete reversal and Recurarization during reversal procedure. Planned start May 2026; status: authorised.
02
Drugs
Sugammadex
03
Conditions
neuromuscular block (NMB)
Beyond the preview
Go deeper on 2025-521946-82-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521946-82-00.